Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised shares of Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price objective on the stock in a research report on Thursday, July 11th.

Brainstorm Cell Therapeutics Stock Up 5.8 %

Shares of Brainstorm Cell Therapeutics stock traded up $0.01 during mid-day trading on Tuesday, hitting $0.26. The stock had a trading volume of 726,722 shares, compared to its average volume of 802,091. The firm has a market cap of $18.15 million, a P/E ratio of -0.81 and a beta of 0.37. The firm has a 50-day moving average of $0.37 and a two-hundred day moving average of $0.43. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $1.81.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. Sell-side analysts expect that Brainstorm Cell Therapeutics will post -0.14 earnings per share for the current year.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned about 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.